EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Combined monophosphoryl lipid A and alpha-Galactosyl ceramide adjuvants enhance the systemic immune response to intranasal inactivated influenza vaccination in a murine homologous challenge model

Thi Len Ho iD, Thanh Tam Pham, Eun-Ju Ko iD

PLOS One · 11.11.2026 · 21 (11) · e0362356

DOI: 10.1371/journal.pone.0362356 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 11.11.2026. Verfasst von Thi Len Ho und 2 weiteren Autor:innen. Beteiligte Einrichtung: Interdisciplinary Graduate Program in Advanced Convergence Technology and Science, Jeju National University, Jeju, Republic of Korea. Hauptthemen laut MEDLINE: Galactosylceramides, Lipid A, Adjuvants, Immunologic, Influenza Vaccines. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, NRF-Basic Science Research Program, Jeju ANCHOR Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inactivated influenza vaccines (IIVs) often fail to provide robust mucosal protection, necessitating the development of potent adjuvants for intranasal delivery. This study evaluated a novel adjuvant combination of Monophosphoryl lipid A (MPL), a TLR4 agonist, and alpha-Galactosyl Ceramide (α-GalCer), an NKT cell ligand, to enhance the efficacy of an intranasal inactivated A/PR8 (iPR8) influenza vaccine. In vitro results demonstrated that MPL+ α-GalCer increased the frequencies of CD4⁺ CD25⁺ , CD8⁺ CD25⁺ and CD4⁺ CD69⁺ T cells relative to both the vehicle control and either single adjuvant in splenocyte cultures, whereas in purified dendritic cell and macrophage cultures MPL+ α-GalCer was no more effective than MPL alone. Splenocyte supernatants showed higher elevated TNF- α, IL-2, IFN-γ, IL-4, and IL-13. This pre-activation drove robust allogeneic T-cell proliferation in a mixed lymphocyte reaction, indicating enhanced allostimulatory capacity rather than influenza-specific priming. In vivo , a single intranasal dose of iPR8+ MPL+ α-GalCer elicited high systemic IgG titers and was effective at inducing Th1-associated IgG2a alongside IgG1. Following an LD50-range PR8 challenge, the combined-adjuvant group showed 100% survival, which was not statistically significant and lower lung viral titers at 7 days post-infection. This group exhibited elevated post-challenge lung-associated antigen-specific IgA and a reduced viral burden, which was accompanied by lower inflammatory cell infiltration and cytokine levels. The protection of combination group was accompanied by increased frequencies of ex vivo antigen-responsive CD4 + and CD8 + T cells recovered post-challenge. Our findings suggest that the MPL+ α-GalCer combination enhances innate and adaptive immune responses, providing an effective adjuvant platform for homologous mucosal protection in a murine model.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GalactosylceramidesLipid AAdjuvants, ImmunologicInfluenza VaccinesOrthomyxoviridae InfectionsAdjuvants, VaccineAnimalsMiceAdministration, IntranasalFemaleCytokinesMice, Inbred BALB CVaccinationVaccines, InactivatedToll-Like Receptor AgonistsAntibodies, ViralImmunoglobulin G

Substanzen

monophosphoryl lipid AGalactosylceramidesalpha-galactosylceramideLipid AAdjuvants, ImmunologicInfluenza VaccinesCytokinesVaccines, InactivatedToll-Like Receptor AgonistsAdjuvants, Vaccine

Autor:innen und Institutionen

  • Interdisciplinary Graduate Program in Advanced Convergence Technology and Science, Jeju National University, Jeju, Republic of Korea.
  • Department of Veterinary Medicine, College of Veterinary Medicine, Jeju National University, Jeju, Republic of Korea.
  • Veterinary Medical Research Institute, Jeju National University, Jeju, Republic of Korea.

ORCID-Profile: Thi Len Ho, Eun-Ju Ko

Förderung

  • National Research Foundation of Korea
  • NRF-Basic Science Research Program
  • Jeju ANCHOR Center

Zitieren

APA

Ho, T. L., Pham, T. T., & Ko, E. J. (2026). Combined monophosphoryl lipid A and alpha-Galactosyl ceramide adjuvants enhance the systemic immune response to intranasal inactivated influenza vaccination in a murine homologous challenge model. PLOS One, 21(11), e0362356. https://doi.org/10.1371/journal.pone.0362356

Vancouver

Ho TL, Pham TT, Ko EJ. Combined monophosphoryl lipid A and alpha-Galactosyl ceramide adjuvants enhance the systemic immune response to intranasal inactivated influenza vaccination in a murine homologous challenge model. PLOS One. 2026;21(11):e0362356. doi:10.1371/journal.pone.0362356

BibTeX
@article{Ho2026,
  author = {Ho, Thi Len and Pham, Thanh Tam and Ko, Eun-Ju},
  title = {Combined monophosphoryl lipid A and alpha-Galactosyl ceramide adjuvants enhance the systemic immune response to intranasal inactivated influenza vaccination in a murine homologous challenge model},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {11},
  pages = {e0362356},
  doi = {10.1371/journal.pone.0362356}
}
Kostenlos starten →